Atopix raises additional development capital to investigate OC459 for treatment of asthma

E

EGBOT

Guest
Atopix raises additional development capital to investigate OC459 for treatment of asthma

HTML:
Atopix Therapeutics Limited, a UK biopharmaceutical company developing a novel class of medicines to treat atopic dermatitis and severe asthma, today announced that it has raised additional development capital to advance its lead product OC459 for the treatment of asthma.

Source: Atopix raises additional development capital to investigate OC459 for treatment of asthma
 

Create an account or login to comment

You must be a member in order to leave a comment

Create account

Create an account on our community. It's easy!

Log in

Already have an account? Log in here.

Latest threads

Back
Top